FLuVac : OPTIMIZATION OF CELL-CULTURE-BASED PRODUCTION OF INFLUENZA VACCINES USING SMALL ELICITING MOLECULES

DESCRIPTION
The laboratory has developed a process to optimize the production rate of Influenza vaccine strains, to be used in cell-culture-based systems of production. This process is based on the use of small molecules related to pro-viral activity, as a booster for vaccine A and B strains production within animal cells. The gain of production reaches +88% over several replication cycles in cell culture.
With the new four-strain flu vaccines coming into the market, this technology provides an efficient tool to optimize manufacturing costs and rate of next-generation vaccines.

STAGE OF DEVELOPMENT
Proof of concept on A549 and MDCK cell culture for
production of A & B recombinant strains with 2 compounds
from the Mdm2 antagonist family :
• Nutlin-3
• NSC68811

INTELLECTUAL PROPERTY
Patent pending in EP, US, CA, CN, JP.
Priority date: November 5th, 2010 (FR1059132)

ADVANTAGES / NOVELTY
• Increased production rates : more doses per production cycle.
•Decreased production time.
• Reduction of Influenza A and B vaccines production costs

APPLICATIONS
Manufacturing optimization of Influenza cell- culture based vaccines.

COLLABORATION TYPE
Pulsalys looks for industrial partners and offers to grant patent license.

CONTACT
Daphné THOMAS
Tech Transfer Officer - Health
Tél. : +33 (0) 4 26 23 56 78
daphne.thomas@pulsalys.fr